DGS Capital Management LLC Increases Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

DGS Capital Management LLC grew its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 13,627 shares of the company’s stock after buying an additional 872 shares during the period. DGS Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $246,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the second quarter worth approximately $188,000. Coronation Fund Managers Ltd. bought a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at $1,334,000. Blue Trust Inc. increased its stake in shares of Teva Pharmaceutical Industries by 164.0% in the 2nd quarter. Blue Trust Inc. now owns 10,434 shares of the company’s stock worth $170,000 after purchasing an additional 6,481 shares in the last quarter. Raymond James & Associates raised its holdings in Teva Pharmaceutical Industries by 5.1% in the 2nd quarter. Raymond James & Associates now owns 815,944 shares of the company’s stock worth $13,259,000 after purchasing an additional 39,610 shares during the period. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in Teva Pharmaceutical Industries by 40.3% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 289,279 shares of the company’s stock valued at $4,701,000 after purchasing an additional 83,117 shares during the period. Institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $16.50 on Friday. The firm has a fifty day simple moving average of $17.51 and a two-hundred day simple moving average of $17.39. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The stock has a market capitalization of $18.69 billion, a P/E ratio of -19.41, a PEG ratio of 1.04 and a beta of 0.79. Teva Pharmaceutical Industries Limited has a 52 week low of $9.90 and a 52 week high of $19.31.

Analyst Ratings Changes

Several equities analysts have weighed in on TEVA shares. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.